Combating AMR and Cancer
Bugworks (bugworksresearch.com) scores 74 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 41st percentile of 18908 Healthcare brands.
Bugworks is a clinical-stage biopharmaceutical company focused on developing novel, affordable, and accessible therapies to address antimicrobial resistance (AMR) and cancer. Led by experienced scientists, the company develops next-generation antibacterial agents and cancer therapeutics aimed at unmet medical needs where existing treatments are insufficient. Bugworks positions itself as targeting two major global health crises-drug-resistant infections and cancer-through innovative, cost-conscious drug development, serving healthcare systems, pharmaceutical partners, investors, and patients worldwide.
| Brand Name | Bugworks |
|---|---|
| Domain | bugworksresearch.com |
| Industry | Healthcare |
| Main Competitors | Entasis Therapeutics (65/100), Spero Therapeutics (75/100), Venatorx Pharmaceuticals (74/100), Summit Therapeutics (65/100), Paratek Pharmaceuticals (75/100), Basilea Pharmaceutica (74/100) |
Moz Domain Authority 38/100 vs category average 40 / leader 97 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Bugworks, a clinical stage biopharmaceutical company Harnessing the power of science to develop affordable, accessible, novel therapies against infectious disea" (Meta description: 20 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, + Microdata, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: PHP, Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, X (Twitter), Instagram, GitHub; no detected presence on Facebook, YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Bugworks?", Claude could identify the brand as of October 2026. Bugworks Research is a Bangalore-based biopharmaceutical company focused on developing novel antibiotics to fight antimicrobial resistance (AMR), targeting drug-resistant superbugs. Its lead candidate, BWC0977, is a broad-spectrum antibiotic aimed at treating infections caused by Best known for Developing BWC0977, a novel antibiotic targeting multidrug-resistant gram-negative superbugs.
When asked "Best brands similar to Bugworks?", Claude would recommend Bugworks as of October 2026. It's a notable player in the global fight against antimicrobial resistance, which makes it relevant if someone's asking about innovative antibiotic developers.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Bugworks's main competitors in Healthcare: Entasis Therapeutics (65/100), Spero Therapeutics (75/100), Venatorx Pharmaceuticals (74/100), Summit Therapeutics (65/100), Paratek Pharmaceuticals (75/100).
Sources: Brand Analyzer scan
Bugworks has low AI-search visibility, scoring 24/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 41, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Bugworks official site
Bugworks scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Bugworks official site
Bugworks is a clinical-stage biopharmaceutical company that develops novel therapeutics aimed at combating antimicrobial resistance (AMR) and cancer. It is led by experienced scientists and focuses on creating affordable, accessible treatments for conditions where current therapies are inadequate.
Sources: Bugworks official site
Bugworks can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Bugworks official site
Bugworks develops next-generation antibacterial agents to combat drug-resistant infections and cancer therapeutics to address unmet medical needs. The company's work centers on harnessing scientific research to create novel treatments that are both affordable and accessible to patients and healthcare systems facing antimicrobial resistance and cancer challenges.
Sources: Bugworks official site
Bugworks' offerings are intended for healthcare systems seeking new treatment options, pharmaceutical partners collaborating on drug development, investors funding biopharmaceutical innovation, and ultimately patients affected by drug-resistant infections and cancer who require novel, affordable therapeutic options.
Sources: Bugworks official site
Bugworks is known for its dedicated focus on developing novel antibacterial agents to fight antimicrobial resistance (AMR), alongside cancer therapeutics. The company distinguishes itself through an emphasis on affordability and accessibility in addressing these two major global health threats, positioning itself as a specialized clinical-stage biopharmaceutical innovator in this space.
Sources: Bugworks official site
Bugworks scores 24/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Bugworks has a weak AI-visibility profile at 24/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (0/100). It benefits from open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 38/100. In a live check, Claude could already identify Bugworks from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Bugworks: British Society for Genetic Medicine (BSGM) (74/100), BSAVA Library (74/100), Cabaletta Bio (74/100), Cactus Life Sciences (74/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.